Aegerion Pharmaceuticals Inc (AEGR.O) Key Developments | Reuters.com
Edition:
United States

Aegerion Pharmaceuticals Inc (AEGR.O)

AEGR.O on Nasdaq

1.54USD
24 Jun 2016
Change (% chg)

$-0.13 (-7.78%)
Prev Close
$1.67
Open
$1.58
Day's High
$1.69
Day's Low
$1.52
Volume
3,046,851
Avg. Vol
956,922
52-wk High
$20.45
52-wk Low
$1.23

Latest Key Developments (Source: Significant Developments)

Aegerion Pharmaceuticals, Inc. appoints gregory perry as chief financial officer
Thursday, 25 Jun 2015 07:30am EDT 

Aegerion Pharmaceuticals, Inc:Appoints gregory perry as chief financial officer.Perry replaces david aubuchon, interim CFO, who will continue in his role as chief accounting officer of Aegerion.  Full Article

Aegerion Pharmaceuticals announces resignation of chief financial officer
Thursday, 14 May 2015 05:00pm EDT 

Aegerion Pharmaceuticals Inc:Announced that Mark Fitzpatrick, Aegerion's chief financial officer (CFO), has resigned.David Aubuchon, Aegerion's chief accounting officer, will serve as acting CFO in the interim.  Full Article

Aegerion Pharmaceuticals Inc reiterates FY 2015 sales guidance
Monday, 4 May 2015 04:10pm EDT 

Aegerion Pharmaceuticals Inc:Reiterates FY 2015 total net product sales guidance at between $205 and $235 million.FY 2015 revenue of $218 million - Thomson Reuters I/B/E/S.  Full Article

Aegerion Pharmaceuticals Inc reaffirms FY 2015 revenue guidance - Conference Call
Thursday, 26 Feb 2015 05:00pm EST 

Aegerion Pharmaceuticals Inc:Continues to expect total net product sales to be between $205 million and $235 million in FY 2015, including between $195 million and $215 million for JUXTAPID and between $10 million and $20 million for MYALEPT.FY 2015 revenue of $216 million - Thomson Reuters I/B/E/S.  Full Article

Aegerion Pharmaceuticals gives Q4 2014 revenue guidance above analysts' estimates; narrows FY 2014 revenue guidance to a range above analysts' estimates; Updates FY 2015 revenue guidance
Monday, 12 Jan 2015 07:00am EST 

Aegerion Pharmaceuticals Inc:Expects Q4 2014 unaudited net product sales to be between $49.3 - $51.3 mln.Expects FY 2014 unaudited net product sales to be between $156 - $158 mln.Says total FY 2015 global net product sales expectations represent an annual growth rate of about 30-50 pct over 2014 net product sales.Q4 2014 revenue of $47.5 mln - Thomson Reuters I/B/E/S.FY 2014 revenue of $154 mln - Thomson Reuters I/B/E/S.FY 2015 revenue of $208 mln - Thomson Reuters I/B/E/S.  Full Article

Aegerion Pharmaceuticals Inc completes acquisition of MYALEPT
Monday, 12 Jan 2015 07:00am EST 

Aegerion Pharmaceuticals Inc:Has completed acquisition of MYALEPT (metreleptin) for injection, an orphan drug product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy (GLD).Execution of asset purchase agreement setting forth terms of acquisition was announced on Nov. 6, 2014.Aegerion paid $325 mln upfront to acquire global rights to develop, manufacture and commercialize MYALEPT, subject to an existing distributor license with Shionogi covering Japan, South Korea and Taiwan.  Full Article

Aegerion Pharmaceuticals, Inc. acquires Myalept from AstraZeneca PLC
Thursday, 6 Nov 2014 02:11am EST 

Aegerion Pharmaceuticals, Inc:Enters into a definitive agreement with AstraZeneca to acquire Myalept (metreleptin for injection), an orphan product.Says under the terms of the agreement, Aegerion will pay AstraZeneca $325 mln upfront to acquire the global rights to develop, manufacture and commercialize Myalept.This is subject to an existing distributor license with Shionogi covering Japan, South Korea, and Taiwan.Transaction does not include the transfer of any AstraZeneca employees or facilities.Expect the transaction to complete in January 2015.  Full Article

Aegerion Pharmaceuticals Inc lowers FY 2014 revenue guidance; gives FY 2015 revenue guidance
Thursday, 30 Oct 2014 04:08pm EDT 

Aegerion Pharmaceuticals Inc:Expects FY 2014 JUXTAPID net product sales to be between $150 and $160 million, revised from the previous expectation of the lower end of the range of between $180 and $200 million.Expects FY 2015 revenue growth of between 30pct and 40pct over FY 2014 projected revenue.FY 2014 revenue of $172 million - Thomson Reuters I/B/E/S.FY 2015 revenue of $292 million - Thomson Reuters I/B/E/S.  Full Article

Aegerion Pharmaceuticals Inc prices $300 mln convertible senior notes offering
Tuesday, 12 Aug 2014 08:47am EDT 

Aegerion Pharmaceuticals Inc:Announced the pricing of its offering of $300 million aggregate principal amount of 2.00 pct convertible senior notes due 2019 to persons that they reasonably believe to be qualified institutional buyers.Says it hsa also granted an option to the initial purchasers of the notes to purchase up to an additional $45.0 million aggregate principal amount of notes to cover overallotments.Notes will bear interest at a rate of 2.00 pct per year, payable semi-annually.Intends to use the net proceeds from the offering, together with the proceeds from its entrance into the warrant transactions, for working capital and other general corporate purposes.  Full Article

Aegerion Pharmaceuticals Inc announces intention to offer $250 mln of convertible notes
Monday, 11 Aug 2014 06:57am EDT 

Aegerion Pharmaceuticals Inc:Intention to offer $250 mln aggregate principal amount of convertible senior notes due 2019.Aegerion also expects to grant the initial purchasers an option to purchase up to an additional $37.5 mln aggregate principal amount of notes to cover overallotments.Aegerion intends to use net proceeds from the offering, together with the proceeds from its entrance into the warrant transactions, for working capital and other general corporate purposes.  Full Article